Feedback (FDBK)

Sector:

Health Care

Index:

FTSE AIM All-Share

 20.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 140.00p
  • 52 Week Low: 19.50p
  • Currency: UK Pounds
  • Shares Issued: 13.33m
  • Volume: 0
  • Market Cap: £2.73m
  • RiskGrade: 267
  • Beta: 0.43

Feedback's Bleepa chosen by CVS equine division

By Josh White

Date: Friday 16 Jul 2021

LONDON (ShareCast) - (Sharecast News) - Medical imaging technology company Feedback announced on Friday that UK veterinary provider CVS Group has appointed 'Bleepa' as its clinical communications platform for its equine division.
The AIM-traded firm said that, following a successful pilot trial, CVS had adopted Bleepa for initial use in the division, with the platform to be rolled-out across 20 equine specialist surgeries.

It said the current agreement would result in increased Bleepa users, and provide scope for a broader relationship with CVS.

Additionally, the Feedback board said the deal highlighted the scalability of Bleepa, and the company's ability to target non-NHS markets by tailoring the platform.

As part of the pilot, Feedback worked with CVS to adapt Bleepa, providing the features needed for veterinary service, both within the surgery and in the field.

Feedback said that previously, vets were not able to easily acquire x-rays in a field and share them with colleagues.

Bleepa developed an image push capability that enabled x-rays to be "securely pushed" from the x-ray machine over a cellular network to the Bleepa platform.

The platform then made these images available to specialists for immediate review and discussion, allowing the correct treatment guidance for the injured animal to be communicated to the vet and be provided at first visit.

That capability meant that images could now be taken "in any location", and could be "instantly shared" with specialist colleagues for timely advice and guidance.

Feedback said the technology had "clear applications" in both military and rural care delivery in developing countries.

"CVS is an important partner for Feedback and we are delighted to now be working with them officially," said chief executive officer Tom Oakley.

"Their validation of our technology and expertise demonstrates the flexibility of Bleepa within new markets.

"By purchasing Bleepa, CVS have evidenced a real commitment to empower their vets by connecting them with specialist colleagues at the point of care, ultimately resulting in excellent animal care at the touch of a button, anywhere in the world."

At 1351 BST, shares in Bleepa were up 2.42% at 0.85p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Feedback Market Data

Currency UK Pounds
Share Price 20.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 140.00p
52 Week Low 19.50p
Volume 0
Shares Issued 13.33m
Market Cap £2.73m
Beta 0.43
RiskGrade 267

Feedback Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
22.85% above the market average22.85% above the market average22.85% above the market average22.85% above the market average22.85% above the market average
88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average
Price Trend
91.93% below the market average91.93% below the market average91.93% below the market average91.93% below the market average91.93% below the market average
89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average
Income Not Available
Growth
45.59% above the market average45.59% above the market average45.59% above the market average45.59% above the market average45.59% above the market average
77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 1
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Feedback Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

Feedback Key Personnel

CEO Tom Oakley
CFO Anesh Patel

Top of Page